Silybin-phosphatidylcholine complex

Alternative Medicine Review

Volumn 14, Issue 4, 2009, Pages 385-390

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RECOMBINANT ALPHA2B INTERFERON; SILIBININ; SILIBININ PHOSPHATIDYLCHOLINE COMPLEX; SILIPHOS; SILYMARIN; UNCLASSIFIED DRUG;

ALCOHOL LIVER DISEASE; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; CHRONIC ACTIVE HEPATITIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; HEARTBURN; HEPATITIS; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; NAUSEA; NONHUMAN; PROSTATE CANCER; RECOMMENDED DRUG DOSE; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTIOXIDANTS; EVIDENCE-BASED MEDICINE; HEPATITIS; HUMANS; LIVER CIRRHOSIS; PHYTOTHERAPY; PROTECTIVE AGENTS; SILYMARIN;

EID: 74049127610     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. No authors listed. Silybum marianum. In: Czap K, Miller AL, Head KA, et al, eds. Alternative Medicine Review Monographs Volume One. Dover, ID: Thorne Research, Inc.; 2002:388-393.
2. www.indena.com/pdf/ephytosome.pdf [Accessed October 9, 2009]
3. Conti M, Malandrino S, Magistretti MJ. Protective activity of silipide on liver damage in rodents. Jpn J Pharmacol 1992;60:315-321.
4. Hikino H, Kiso Y, Wagner H, Fiebig M. Antihepatotoxic actions of flavonolignans from Silybum marianum fruits. Planta Med 1984;50:248-250.
5. Enjalbert F, Rapior S, Nouguier-Soule J, et al. Treatment of amatoxin poisoning: 20-year retrospective analysis. J Toxicol Clin Toxicol 2002;40:715-757.
6. Pradhan SC, Girish C. Hepatoprotective herbal drug, Silymarin from experimental pharmacology to clinical medicine. Indian J Med Res 2006;124:491-504.
7. Manach C, Scalbert A, Morand C, et al. Polyphenols: food sources and bioavailability. Am J Clin Nutr 2004;79:727-747.
8. Bombardelli E, Curri SB, Delia Loggia R, et al. Complexes between phospholipids and vegetal derivatives of biological interest. Fitoterapia 1989;90:1-9.
9. No authors listed. Phosphatidylcholine. In: Czap K, Miller AL, Head KA, et al, eds. Alternative Medicine Review Monographs Volume One. Dover, ID: Thorne Research, Inc.; 2002:310-315.
10. Kidd PM. Bioavailability and activity of phytosome complexes from botanical polyphenols: the Silymarin, curcumin, green tea, and grape seed extracts. Altern Med Rev 2009;14:226-246.
11. Kidd P, Head K. A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybinphosphatidylcholine complex (Siliphos). Altern Med Rev 2005;10:193-203.
12. Barzaghi N, Crema F, Gatti G, et al. Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects. Eur J Drug Metab Pharmacokinet 1990;15:333-338.
13. Schandalik R, Gatti G, Perucca E. Pharmacokinetics of silybin in bile following administration of silipide and Silymarin in cholecystectomy patients. Arzneimittelforschung 1992;42:964-968.
14. Schandalik R, Perucca E. Pharmacokinetics of silybin following oral administration of silipide in patients with extrahepatic biliary obstruction. Drugs Exp Clin Res 1994;20:37-42.
15. No authors listed. Glutathione. In: Czap K, Miller AL, Head KA, et al, eds. Alternative Medicine Review Monographs Volume One. Dover, ID: Thorne Research, Inc.; 2002:184-192.
16. Valenzuela A, Aspillaga M, Vial S, Guerra R. Selectivity of Silymarin on the increase of the glutathione content in different tissues of the rat. Planta Med 1989;55:420-422.
17. Kidd PM. Phosphatidylcholine: a superior protectant against liver disease. Altern Med Rev 1996;1:258-274.
18. Marena C, Lampertico M. Preliminary clinical development of silipide: a new complex of silybin in toxic liver disorders, Planta Med 1991;57:A124-A125.
19. Marcelli R, Bizzoni P, Conte D, et al. Randomized controlled study of the efficacy and tolerability of a short course of IdB 1016 in the treatment of chronic persistent hepatitis. Eur Bull Drug Res 1992;1:131-135.
20. Buzzelli G, Moscarella S, Giusti A, et al. A pilot study on the liver protective effect of silybinphosphatidylcholine complex (IdB1016) in chronic active hepatitis. Int J Clin Pharmacol Ther Toxicol 1993;31:456-460.
21. Moscarella S, Giusti A, Marra F, et al. Therapeutic and antilipoperoxidant effects of silybinphosphatidylcholine complex in chronic liver disease: preliminary results. Curr Ther Res 1993;53:98-102.
22. Vailati A, Aristia L, Sozze E, et al. Randomized open study of the dose-effect relationship of a short course of IdB 1016 in patients with viral or alcoholic hepatitis. Fitoterapia 1993;94:219-228.
23. Buzzelli G, Moscarella S, Barbagli S, et al. Therapeutic effect of silipide in patients with chronic hepatitis C non-responders (NRs) to interferon (IFN) treatment. J Hepatol 1994;21:17.
24. Orlando R, Fragasso A, Lampertico M, et al. Pharmacokinetic studies of silybinphosphatidylcholine complex (IdB 1016) in liver cirrhosis after multiple doses. Med Sci Res 1991;19:827-828.
25. Orlando R, Fragasso A, Lampertico M, et al. Silybin kinetics in patients with liver cirrhosis: a comparative study of a silybin-phosphatidylcholine complex and Silymarin. Med Sci Res 1990;18:861-863.
26. Indena. IdB-1016 silybin phosphatidylcholine complex update. Drugs Future 1992;17:248.
27. Indena. Siliphos (TM). From Silybum marianum (L.) Gaertn. a new natural preventive targeted at the liver. Seattle, WA: Indena USA Inc.; 2004.www.indenausa. com.
28. Bares JM, Berger J, Nelson JE, et al. Silybin treatment is associated with reduction in serum ferritin in patients with chronic hepatitis C. J Clin Gastroenterol 2008;42:937-944.
29. Flaig TW, Gustafson DL, Su LJ, et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs 2007;25:139-146.